论文部分内容阅读
目的观察早期单唾液酸四己糖神经节苷脂(申捷)联合丹红注射液治疗急性脑梗死的临床疗效。方法将120例急性脑梗死患者随机分为3组,每组各40例,3组患者均予常规对症治疗。观察组在常规治疗基础上加用申捷40mg,静脉滴注,1次/d,共15d;丹红注射液40ml,静脉滴注,1次/d,共15d。对照组A在常规治疗的基础上加用申捷40mg,溶于0.9氯化钠注射液250ml中静脉滴注,1次/d,15d为1个疗程。对照组B在常规治疗基础上加用丹红注射液40ml/次,静脉滴注,1次/d,共15d。观察3组临床疗效及神经功能评分。结果观察组有效率为75.0%,显著高于对照组A、B的50.0%,两组比较具有统计学意义(P<0.05)。3组MMSE、ADL、SSS、HAMD评分与治疗前比较均好转(P<0.05),但观察组治疗效果显著优于单纯加用神经节苷脂或者丹红注射液治疗(P<0.05)。结论申捷联合丹红注射液治疗急性脑梗死临床疗效满意。
Objective To observe the clinical efficacy of early monosialotetrahexosyl ganglioside (Shenjie) combined with Danhong injection in the treatment of acute cerebral infarction. Methods 120 patients with acute cerebral infarction were randomly divided into 3 groups, 40 cases in each group, 3 patients were routine symptomatic treatment. The observation group was treated with Shenjie 40mg intravenously and once daily for 15 days on the basis of routine treatment. Danhong injection 40ml was intravenously dripped once daily for 15 days. The control group A was treated with Shenjie 40mg on the basis of routine treatment, dissolved in 0.9ml sodium chloride 250ml intravenous infusion, once / d, 15d for a course of treatment. The control group B was treated with Danhong injection 40ml / time on the basis of routine treatment, intravenous infusion, once / d for 15 days. The clinical efficacy and neurological score of the three groups were observed. Results The effective rate of the observation group was 75.0%, which was significantly higher than that of the control group A and B (50.0%). There was significant difference between the two groups (P <0.05). The scores of MMSE, ADL, SSS and HAMD in three groups were all improved (P <0.05) compared with before treatment, but the treatment effect in the observation group was significantly better than that in the group treated with ganglioside alone or Danhong injection (P <0.05). Conclusion Shenjie injection combined with Danhong effective treatment of acute cerebral infarction.